Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis

Last updated: December 13, 2024
Sponsor: University Hospital, Basel, Switzerland
Overall Status: Active - Recruiting

Phase

N/A

Condition

Multiple Sclerosis

Neurologic Disorders

Scar Tissue

Treatment

MRI

Neurocognitive examination for healthy subjects

blood sampling

Clinical Study ID

NCT05177523
2018-01174; me18Granziera
  • Ages 18-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This project is to:

  1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients.

  2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period.

  3. Validate the combination of imaging parameters that best differentiate aMS versus naPMS patients using histopathology.

Eligibility Criteria

Inclusion

Inclusion Criteria for patients:

  • Patients may be diagnosed with:

  1. active RRMS (n=100): Relapsing-remitting course and > 1 clinical relapse and/or signs of MRI activity (> 1 Gd enhancing lesion) during the last year before study enrollment.

  2. non-active PMS (n=100): Progressive course (PPMS or SPMS) and no clinical relapses and/or signs of MRI activity during the last year before study enrollment.

  • Age 18-80 years old

  • No other neurological or psychiatric disorder

Inclusion criteria for healthy controls:

  • Age 18-80 years old

  • No other neurological or psychiatric disorder

Exclusion Criteria for patients and healthy controls:

  • Pregnancy

  • Contraindication to MRI (eg, claustrophobia, metallic implants, pacemaker etc).

  • Inability to give consent

Study Design

Total Participants: 300
Treatment Group(s): 3
Primary Treatment: MRI
Phase:
Study Start date:
September 04, 2018
Estimated Completion Date:
December 31, 2028

Study Description

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by multifocal inflammatory infiltrates, microglial activation and degradation of oligodendrocytes, myelin and axons. Clinical MS categories exhibit variable amount of central nervous system (CNS) damage and repair, depending on numerous variables including genetic, immunological, pathological and environmental factors.

Therefore, understanding the interplay between axonal damage (i.e. axonal demyelination/degeneration/loss/disorganization) and (ii) axonal repair (i.e. axonal remyelination/reorganization) in living MS patients may be the key to understand disease progression, to establish accurate disease monitoring criteria and to predict disease response to future reparative therapies. New in-vivo methods are necessary to elucidate the interplay between axonal damage and repair in the brain of living patients with MS. Advanced MRI (aMRI) permits a multifaced quantification of the various components of the axons and their organization. Neurite Orientation Dispersion and Density Imaging (NODDI) and Diffusion Kurtosis (DK) are new approaches in clinical research This study is to identify in vivo the specific neuropathological pattern of axonal damage and repair exhibited by active MS (aMS) and non-active progressive MS (naPMS) patient by leveraging the information provided by model-based diffusion metrics (NODDI, DK), Magnetization Transfer Imaging (MTI), Multi-echo Susceptibility-Based imaging (SBI), Myelin Water Imaging (MWI) and quantitative T1 relaxometry (qT1). These advanced MRI contrasts provide complementary and partially redundant information about the axonal structure and its organization (i.e. density and orientation of axons and dendrites in the brain tissue, axonal integrity and myelination, presence of myelin and iron, and brain tissue architecture). Therefore, their combination may prove high sensitivity and specificity to axonal damage and repair.

This project has 3 main aims:

Aim 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients.

Aim 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period.

Aim 3. Validate the combination of imaging parameters that best differentiate aMS versus naPMS patients using histopathology.

Connect with a study center

  • University Hospital Basel, Department of Neurology

    Basel, 4031
    Switzerland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.